TRAM-01: A phase 2 study of trametinib for pediatric patients with neurofibromatosis type 1 and plexiform neurofibromas
Neuro-Oncology · 01.09.2026 · 28 (9) · 2279-2288
DOI: 10.1093/neuonc/noag112 ↗Kurz gefasst
Klinische Studie (Phase II) in der Zeitschrift Neuro-Oncology, online erschienen am 19.05.2026. Verfasst von Dorsa Sadat Kiaei und 34 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurosciences, University of Montreal, CHU Sainte-Justine, Montreal, Canada. Hauptthemen laut MEDLINE: Antineoplastic Agents, Neurofibroma, Plexiform, Neurofibromatosis 1, Protein Kinase Inhibitors. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: CIHR, CHU Sainte-Justine.
Abstract (Originalsprache)
Background
Plexiform neurofibromas (PNs) are observed in up to 50% of patients with neurofibromatosis type 1 (NF1). Trametinib has been used widely to treat PNs but limited data has been reported on its efficacy within a clinical trial. We conducted a phase 2 trial with trametinib for patients with NF1 and inoperable PNs.
Methods
Patients with NF1 and inoperable PNs aged ≥1 month to ≤25 years when starting trametinib were eligible. Patients received trametinib once daily orally continuously for a maximum of 18 cycles of 28 days. Patients completed patient-reported outcome measures. Response evaluations were performed after cycle 3, 6, 12 and at the end of treatment and then every 6 months. The PN volumes were centrally quantified using a semi-automatic 3D segmentation method.
Results
Forty-six patients were recruited. The median age was 11.1 years (range 0.7-19.8). The median baseline tumor volume was 104.6 ml (range 16.3 to 650.1 ml). Volumetric assessment demonstrated an overall response rate (volume decrease of ≥20%) in 47.8% (22/46) of patients. Median volume change was −19.3% (range −80.5 to 3.5). Forty-one patients (89.1%) completed the planned treatment. The 3 years progression free survival and the event free survival were respectively 73.1% (95% CI 53.3%-85.5%) and 47.1% (95% CI 28.8-63.5).
Conclusions
We report outcomes and volumetric response of PNs treated with trametinib within a phase 2 trial. Based on these results, trametinib is effective and overall well tolerated.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurosciences, University of Montreal, CHU Sainte-Justine, Montreal, Canada.
- Department of Pediatrics, Division of Hematology and Oncology, Pennsylvania State Health Children's Hospital, Hershey, Pennsylvania, USA.
- Department of Pediatrics, Division of Hematology-Oncology, CHU de Québec-Université Laval, Québec, Canada.
- Department of Psychology, Université de Montréal, Montréal, Canada.
- Centre de recherche Azrieli, CHU Sainte-Justine, Montreal, Canada.
- Department of Pharmacology, CHU Sainte Justine, Montreal, Canada.
ORCID-Profile: Dorsa Sadat Kiaei, Maxime Caru, Emma Clini, Sarah Lippé, Yves Théoret, Jean-Claude Décarie, Uri Tabori, Cynthia Hawkins, Benjamin Ellezam, Luis H Ospina, Léandra Desjardins, Marie-Élaine Métras, Karim Estephan, Stéphanie Vairy, Éric Bouffet, Vijay Ramaswamy, Juliette Hukin, Tiffany Rent, Craig Erker, Nada Jabado, Mathieu Dehaes, Sébastien Perreault
Förderung
- CIHR
- CHU Sainte-Justine
Zitieren
APA
Sadat Kiaei, D., Caru, M., Larouche, V., Clini, E., Pugalenthi Saravanan, D., Lippé, S., Théoret, Y., Décarie, J. C., Tabori, U., Hawkins, C., Ellezam, B., Ospina, L. H., Desjardins, L., Métras, M. É., Sultan, S., Cantin, É., Routhier, M. È., Mailloux, C., Bertrand, M. C., …, & Perreault, S. (2026). TRAM-01: A phase 2 study of trametinib for pediatric patients with neurofibromatosis type 1 and plexiform neurofibromas. Neuro-Oncology, 28(9), 2279-2288. https://doi.org/10.1093/neuonc/noag112
Vancouver
Sadat Kiaei D, Caru M, Larouche V, Clini E, Pugalenthi Saravanan D, Lippé S, et al. TRAM-01: A phase 2 study of trametinib for pediatric patients with neurofibromatosis type 1 and plexiform neurofibromas. Neuro-Oncology. 2026;28(9):2279-2288. doi:10.1093/neuonc/noag112
BibTeX
@article{SadatKiaei2026,
author = {Sadat Kiaei, Dorsa and Caru, Maxime and Larouche, Valérie and Clini, Emma and Pugalenthi Saravanan, Deepika and Lippé, Sarah and Théoret, Yves and Décarie, Jean-Claude and Tabori, Uri and Hawkins, Cynthia and Ellezam, Benjamin and Ospina, Luis H and Desjardins, Léandra and Métras, Marie-Élaine and Sultan, Serge and Cantin, Édith and Routhier, Marie-Ève and Mailloux, Chantal and Bertrand, Marie-Claude and Estephan, Karim and McKeown, Tara and Vairy, Stéphanie and Legault, Geneviève and Renzi, Samuele and Bouffet, Éric and Ramaswamy, Vijay and Coltin, Hallie and Lafay-Cousin, Lucie and Hukin, Juliette and Alves, Mélanie and Rent, Tiffany and Erker, Craig and Jabado, Nada and Dehaes, Mathieu and Perreault, Sébastien},
title = {TRAM-01: A phase 2 study of trametinib for pediatric patients with neurofibromatosis type 1 and plexiform neurofibromas},
journal = {Neuro-Oncology},
year = {2026},
volume = {28},
number = {9},
pages = {2279--2288},
doi = {10.1093/neuonc/noag112}
}
EUVIMED